20-F: MediWound 2025 Annual Report: Losses Persist Amid R&D Push

MediWound Ltd. reported a net loss of $23.9 million for 2025, a decrease from $30.2 million in 2024, as it continues significant investments in R&D and manufacturing expansion for NexoBrid and EscharEx.

Summary

• Net loss for 2025 was $23.9 million, an improvement from $30.2 million in 2024.
• Total revenues decreased to $17.0 million in 2025 from $20.2 million in 2024, primarily due to U.S. government shutdown delays and lower product sales by Vericel.
• Operating loss increased to $25.3 million in 2025 from $19.4 million in 2024.
• Research and development expenses increased significantly by 61% to $14.3 million in 2025, mainly driven by the EscharEx VALUE Phase III trial.
• The expanded NexoBrid manufacturing facility in Yavne, Israel, is fully operational as of the end of 2025, increasing production capacity sixfold, with commercial availability subject to regulatory approvals expected in 2026.
• EscharEx, for venous leg ulcers (VLUs), initiated a global pivotal Phase III trial (VALUE) in February 2025, enrolling 216 patients across 40 sites in the U.S. and Europe.
• A Phase II study of EscharEx in diabetic foot ulcers (DFUs) is planned for initiation in the second half of 2026.
• Received $3.6 million in additional funding from the U.S. Department of War (DoW) in 2025 to advance development of a room temperature-stable NexoBrid formulation.
• Completed a registered direct offering in September 2025, raising gross proceeds of $30.0 million.
• NexoBrid received approval for use in Australia in adult and pediatric burn patients in September 2025, expanding approved markets to 45 countries worldwide.
• The company had cash and cash equivalents and short-term and restricted bank deposits totaling $53.6 million as of December 31, 2025.
• Accumulated deficit reached $228.9 million as of December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While the net loss improved and there are significant advancements in clinical trials and manufacturing capacity, the decline in revenues and increased operating loss, coupled with ongoing geopolitical and regulatory risks, indicate continued financial challenges and uncertainty.

Positives

• Net loss decreased to $23.9 million in 2025 from $30.2 million in 2024, indicating an improvement in bottom-line performance.
• The expanded NexoBrid manufacturing facility is fully operational as of the end of 2025, increasing production capacity sixfold to support growing global demand.
• NexoBrid received approval in Australia for adult and pediatric burn patients in September 2025, expanding its market presence to 45 countries.
• EscharEx initiated a global pivotal Phase III trial (VALUE) for venous leg ulcers in February 2025, marking significant progress in its clinical development.
• The EscharEx program is supported by strategic research collaborations with leading global wound care companies, reflecting strong industry validation.
• Positive results were announced from the U.S. Phase I/II study of MW005 for basal cell carcinoma, with 11 out of 15 patients achieving complete clearance.
• Received $3.6 million in additional funding from the U.S. Department of War (DoW) in 2025 for the development of a room temperature-stable NexoBrid formulation.
• Successfully completed a registered direct offering in September 2025, raising $30.0 million in gross proceeds to support pre-commercial activities and manufacturing.
• The World Health Organization (WHO) recognized enzymatic debridement as a validated treatment for burn injuries, bolstering NexoBrid's role in emergency preparedness.
• An independent global consulting firm estimated a peak sales opportunity of approximately $831 million for EscharEx, indicating substantial market potential.

Negatives

• Total revenues decreased by 15% from $20.2 million in 2024 to $17.0 million in 2025.
• The decrease in revenues was primarily attributed to U.S. government shutdown delays in budget approvals and new contractual agreements, as well as lower product sales by Vericel.
• Net operating loss increased to $25.3 million in 2025 from $19.4 million in 2024.
• Accumulated deficit reached $228.9 million as of December 31, 2025.
• Eleven of the currently issued NexoBrid patents in Europe and other foreign jurisdictions expired in November 2025, and one U.S. patent is set to expire in 2029, reducing competitive advantage.
• NexoBrid's transitional pass-through (TPT) payment status under HCPCS code J7353 expires on December 31, 2026, which could impact future reimbursement.
• The BARDA contract expired in September 2025, and the MTEC contract expired in December 2025, potentially impacting future development service revenues.
• The 'One Big Beautiful Bill Act' enacted in July 2025 imposes significant reductions in Medicaid funding, which could adversely affect sales of commercialized product candidates.
• The current U.S. Presidential administration's strategy to reduce drug costs, including potential tariffs and new regulations ('Globe and Guard'), is likely to negatively impact the pharmaceutical industry and the company's revenues.
• Geopolitical tensions, particularly the Hamas-Israel and Russia-Ukraine conflicts, have contributed to a surge in cyber-attacks targeting Israeli companies, posing a threat to critical infrastructure.
• Fitch downgraded Israel's Long-Term Foreign-Currency Issuer Default Rating to A from A+ in August 2024, and Moody's downgraded Israel's credit rating to Baa1 from A2 in September 2024, which may negatively affect the business environment.
• A limited number of the company's workforce in Israel have been called into active duty due to wars, potentially affecting business operations.

Risks

• Product development is a lengthy and expensive process with an uncertain outcome, including potential negative or inconclusive clinical trial results, slower patient enrollment, or regulatory changes.
• Delays or failure in obtaining regulatory approval for EscharEx and other pipeline product candidates.
• Extensive and ongoing regulatory requirements and obligations for approved products like NexoBrid, with potential for restrictions, recalls, or withdrawal if compliance is not maintained.
• Unanticipated and undesirable side effects or other unknown properties of NexoBrid, EscharEx, or their underlying proteolytic enzymes.
• Regulatory approval for products may be limited to specific indications and conditions, and the prescription of off-label uses could adversely affect the business.
• Inability to expand production or processing capabilities to satisfy future demand, despite the new facility.
• Reliance on a single manufacturing site in Yavne, Israel, which is vulnerable to accidents or force majeure events such as war, missile or terrorist attack, earthquake, major fire or explosion, major equipment failure or power failure.
• Manufacturing risks including contamination, equipment failure, or operator error, leading to reduced production yields, product defects, and other supply disruptions.
• Dependence on a sole supplier (Challenge Bioproducts Corporation Ltd. in Taiwan) for intermediate drug substance bromelain SP, exposing the company to supply interruptions and geopolitical risks related to tensions between the Peoples Republic of China and Taiwan.
• The commercial success of NexoBrid in the U.S. is dependent on the actions of its partner Vericel, including their commercialization efforts and compliance with regulatory requirements.
• Dependence on contracts with MTEC/DoW to fund development activities for NexoBrid for field use in the United States, with risk of suspension or termination due to changes in government budgets and agendas.
• NexoBrid, EscharEx, and pipeline product candidates may not gain market acceptance by physicians, healthcare payors, patients, and others in the medical community.
• Unfavorable pricing regulations or third-party coverage and reimbursement policies, including the expiration of NexoBrid's transitional pass-through (TPT) payment status on December 31, 2026.
• Recently enacted and future legislation in the U.S. (e.g., Inflation Reduction Act, One Big Beautiful Bill Act) and EU (e.g., HTA Regulation) may increase costs, restrict sales, or reduce reimbursement.
• Competition from existing standard of care (surgery, other enzymatic debridement like Smith & Nephew Plc's SANTYL) and new therapies.
• Failure to manage growth effectively could disrupt business operations.
• History of net losses and expectation to incur substantial and increasing net losses, with no guarantee of future profitability.
• Need for additional capital, which may cause dilution to existing shareholders, restrict operations, or require relinquishing rights to pipeline product candidates or intellectual property.
• Inability to access uninsured funds held at financial institutions in Israel and Germany in case of failure.
• Inaccurate business decisions based on inaccurate forecasts of future sales of products and pipeline product candidates.
• Exchange rate fluctuations between the U.S. dollar and the Israeli shekel, the Euro, and other non-U.S. currencies may negatively affect earnings.
• Certain business practices could become subject to scrutiny by regulatory authorities, as well as to lawsuits brought by private citizens, under laws such as the Federal False Claims Act, Anti-Kickback Statute, and HIPAA.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws, regulations, standards, and other requirements (e.g., GDPR, CCPA, Israeli Privacy Protection Law).
• Information technology system failures, cyberattacks, or deficiencies in cybersecurity, exacerbated by geopolitical tensions, could disrupt business and lead to financial losses or legal liability.
• Laws and regulations affecting government contracts make it more costly and difficult to successfully conduct business and retain rights under BARDA contracts.
• Product liability lawsuits could result in costly and time-consuming litigation and significant liabilities.
• Extensive environmental, health, and safety, and other laws and regulations, with potential for substantial capital costs, operating expenses, or penalties for non-compliance.
• The enactment of legislation implementing changes in tax legislation or policies in different geographic jurisdictions (e.g., One Big Beautiful Bill Act, OECD BEPS 2.0) could materially impact the business, financial condition, and results of operations.
• Inability to obtain and maintain protection for the intellectual property relating to, or incorporated into, its technology and products, including patents, trademarks, and trade secrets.
• Expiration of key NexoBrid patents in Europe (November 2025) and other foreign jurisdictions (2025), and one U.S. patent (2029), reducing competitive advantage.
• Inability to enforce covenants not to compete with employees, particularly under Israeli labor laws and potential new U.S. federal restrictions.
• Claims for remuneration or royalties for assigned service invention rights by employees under Israeli Patent Law.
• The market price of ordinary shares may be subject to fluctuation, and future sales of ordinary shares could reduce the market price.
• Reliance on foreign private issuer exemptions from certain SEC and Nasdaq requirements, which could change and increase compliance costs.
• Conditions in Israel, including political, economic, and military conflicts (e.g., wars with Iran, Hamas, Hezbollah), could materially and adversely affect business and operations.
• Provisions of Israeli law and the company's articles of association may delay, prevent, or otherwise impede a merger with, or an acquisition of, the company.
• Israeli government grants for research and development activities require satisfying specified conditions and paying penalties in addition to repayment of the grants upon certain events, restricting technology transfer outside of Israel.
• Difficulty enforcing a judgment of a U.S. court against the company, its officers, and directors or Israeli experts in Israel, or asserting U.S. securities laws claims in Israel.
• Shareholder rights and responsibilities are governed by Israeli law, which differs in some material respects from those of U.S. companies.
• U.S. shareholders may suffer adverse tax consequences if the company is characterized as a passive foreign investment company (PFIC).

Future Outlook

The company expects to continue incurring significant expenses and operating losses in the coming years due to ongoing research and development efforts, particularly for EscharEx clinical trials and other pipeline product candidates. It also plans to advance NexoBrid as a standard of care and expand its commercial reach internationally, including for mass casualty events. The company believes its existing cash and deposits of $53.6 million are sufficient to fund operations and capital expenditures for at least twelve months from the report date, but future capital requirements will depend on revenue growth, milestone payments, and R&D spending.

Management Comments

• We are a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair.
• Our solutions selectively remove non-viable hazardous tissue while preserving healthy tissue, offering a safer and more effective alternative to traditional methods.
• With robust in-house research, development, and manufacturing capabilities, the company produces and commercializes cutting-edge biologics for wound and burn care that exceed existing standards of care, improve patient outcomes, and reduce healthcare costs by eliminating the need for surgical interventions.
• We believe that our existing cash and cash equivalents, short-term and restricted bank deposits of $53.6 million as of December 31, 2025, will be sufficient to fund its operations and capital expenditures for at least twelve months from the date of issuance of these consolidated financial statements.
• We expect to continue to invest in our research and development efforts, including in respect of our EscharEx planned clinical trials, as well as the clinical development and trials of our other pipeline product candidates.
• We expect to continue to advance NexoBrid as a standard of care, and expand its commercial reach in international markets, including for potential use as a medical countermeasure during mass casualty events.

Industry Context

StockSavvy.ai notes that MediWound operates in the highly competitive biopharmaceutical and wound care industries, characterized by significant technological and practice changes. The company's focus on enzymatic debridement positions it against traditional surgical methods and existing enzymatic products like Smith & Nephew Plc's SANTYL. The increasing global focus on non-surgical alternatives and advanced wound care therapies, as well as governmental support for medical countermeasures, aligns with MediWound's strategic direction. However, the industry faces ongoing pressures from healthcare cost containment measures and evolving regulatory landscapes, which could impact pricing and reimbursement.

Comparison to Industry Standards

• EscharEx has shown clinical advantages over the leading enzymatic debridement product, Smith & Nephew Plc's SANTYL, in Phase II studies for Venous Leg Ulcers (VLUs).
• In Phase II VLU studies, EscharEx achieved a statistically significant higher incidence of complete debridement (63% vs. 0% for SANTYL) during the first two weeks of treatment.
• The median time to complete debridement was significantly shorter for EscharEx (9 days vs. not achieved for SANTYL) in Phase II VLU studies.
• The incidence of achieving complete debridement and complete wound bed preparation (WBP) was 50.0% for EscharEx vs. 0% for SANTYL during the daily treatment period in Phase II VLU studies.
• The overall incidence of achieving WBP throughout the Phase II VLU study was 78.3% for EscharEx vs. 37.5% for SANTYL.
• The estimated median time to achieve WBP was 11 days for EscharEx vs. not achieved for SANTYL in Phase II VLU studies.
• Patients reaching WBP with EscharEx were 4 times more likely to achieve wound closure (p=0.004) in Phase II VLU studies.
• Average time to wound closure for patients treated with EscharEx was 48.4 days compared to 76.0 days for SANTYL (p=0.05) in Phase II VLU studies.
• NexoBrid has been investigated in hundreds of patients across more than 22 countries and four continents in ten completed Phase II, Phase III, and post-marketing clinical studies, with over 16,000 burn patients treated since 2013, demonstrating consistency with clinical trial data and no new safety signals.
• The World Health Organization (WHO) has recognized enzymatic debridement as a validated treatment for burn injuries in its BMCI guidelines, supporting NexoBrid's critical role in emergency preparedness.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings, including any such proceedings that are pending or threatened, of which we are aware.

Related Party Transactions

• The Information Rights Agreement with Clal Biotechnology Industries Ltd. (CBI) expired in July 2024 due to CBI's decreased holdings in the company.
• The 2021 Registration Rights Agreement with certain shareholders (including CBI and its affiliates) remains in effect, registering the resale of 1,266,141 CBI shares. Professor Lior Rosenberg and his affiliated entity are no longer party to this agreement.
• The Founders and Shareholders Agreement (January 2001, amended 2006) with CBI, Prof. Lior Rosenberg, and LR, grants a perpetual, exclusive, non-revocable, royalty-free, sub-licensable, worldwide license for intellectual property related to debridement. All fixed payments under this agreement have been made.
• Employment agreements with executive officers include standard provisions for non-competition/solicitation, confidentiality of information, and assignment of inventions.
• CEO Ofer Gonen is entitled to a one-time termination payment of six months of salary upon termination (unless for cause).
• Options and RSUs granted to directors and executive officers may contain acceleration provisions upon certain merger, acquisition, or change of control transactions.
• Indemnification agreements with each director and executive officer exculpate them from liability for damages caused by a breach of duty of care and undertake to indemnify them to the fullest extent permitted by Israeli law, with a maximum indemnification amount.
• Directors and Officers liability insurance has been obtained for office holders.

Stakeholder Impact

• Shareholders face potential dilution from past and future equity offerings, market price fluctuations, and the impact of Israeli law on shareholder rights. U.S. shareholders may suffer adverse tax consequences if the company is characterized as a PFIC. No cash dividends are anticipated in the foreseeable future.
• Employees are impacted by the company's expanding workforce and share-based compensation plans. Employees in Israel may be called for military reserve duty due to ongoing conflicts, potentially affecting business operations.
• Customers may experience delays in product availability due to regulatory approvals for expanded manufacturing. Government budget delays and changes in pricing/reimbursement policies could affect product access and demand. Competition from existing and new therapies may also impact customer choices.
• Suppliers, particularly the sole supplier of bromelain SP in Taiwan, are critical to the company's operations. Geopolitical risks in Taiwan could lead to supply chain disruptions. The company's ability to meet contractual obligations to vendors could be impacted by conflicts in Israel.
• Creditors are exposed to the company's financial performance and liquidity, which could affect its ability to meet financial obligations. The company's cash and deposits are spread among several financial institutions, but uninsured funds pose a risk in case of institutional failure.

Next Steps

• Complete regulatory reviews and approvals for commercial availability of the expanded NexoBrid manufacturing facility (expected in 2026).
• Conduct interim sample size assessment for EscharEx VALUE Phase III trial (expected by year-end 2026).
• Complete enrollment for EscharEx VALUE Phase III trial (expected by year-end 2026).
• Initiate a randomized, head-to-head Phase II study in VLU patients comparing EscharEx to collagenase SANTYL ointment in 2026.
• Initiate a Phase II study of EscharEx in DFUs in the second half of 2026.
• Initiate a prospective, single-arm investigator-initiated trial (IIT) to evaluate EscharEx in pressure ulcers in the second half of 2026.
• Advance development of a room temperature-stable formulation of NexoBrid, including expanded CMC activities, enhancement of in-house manufacturing capabilities, and initial preparations for a clinical trial.
• Continue to locally execute market access strategy for NexoBrid in Europe to obtain procurement by burn centers and hospitals.
• Distributors in other international markets are expected to launch NexoBrid after receipt of local regulatory approval, which may occur in certain markets during 2026.
• The company's foreign private issuer status will be tested again as of June 30, 2026.
• The UK amendment to clinical trials regulations will become applicable on April 28, 2026.
• The company will request shareholder approval for any increase in the pool of shares available under the 2024 Plan.

Key Dates

Recommendation

MediWound is in a critical growth phase with significant R&D investments in promising product candidates like EscharEx, which has shown strong Phase II results and is now in a pivotal Phase III trial. The expansion of NexoBrid manufacturing capacity and recent regulatory approvals are positive. However, the company continues to incur substantial net losses, experienced a revenue decline in 2025, and faces considerable risks related to regulatory approvals, market acceptance, intense competition, supply chain vulnerabilities, and geopolitical instability in Israel and Taiwan. The expiration of key NexoBrid patents also adds to competitive pressure. While the long-term potential of its enzymatic platform is notable, the near-term financial performance and numerous operational risks warrant a cautious 'hold' stance for investors, awaiting clearer signs of sustained revenue growth and successful commercialization of its pipeline.

Keywords

NexoBrid, EscharEx, MW005, enzymatic debridement, burn care, wound care, basal cell carcinoma, biopharmaceutical, SEC filing, 20-F, clinical trials, Phase III, manufacturing capacity, regulatory approval, Israel, Vericel, BARDA, MTEC, intellectual property, financial results, stock offering, corporate governance, risk factors, Medicaid, Inflation Reduction Act